LENZ
LENZ Therapeutics Surpasses Expectations with LNZ100 Launch, Sets Stage for Blockbuster Market Opportunity
LENZ Therapeutics has made significant strides in its launch of LNZ100, a once-daily eye drop designed to address presbyopia. According to recent Q4 2025 conference call highlights, the company has surpassed expectations and is setting the stage for a blockbuster market opportunity. In his opening remarks, Evert Schimmelpennink, President and